Metastatic prostate cancer diagnosed by fine-needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates
dc.contributor.author | Cantley, Richard L. | |
dc.contributor.author | Wang, Xiaoming | |
dc.contributor.author | Reichert, Zachery R. | |
dc.contributor.author | Chinnaiyan, Arul M. | |
dc.contributor.author | Mannan, Rahul | |
dc.contributor.author | Cao, Xuhong | |
dc.contributor.author | Spratt, Daniel E. | |
dc.contributor.author | Vaishampayan, Ulka N. | |
dc.contributor.author | Alumkal, Joshi J. | |
dc.contributor.author | Morgan, Todd M. | |
dc.contributor.author | Palapattu, Ganesh | |
dc.contributor.author | Davenport, Matthew S. | |
dc.contributor.author | Pantanowitz, Liron | |
dc.contributor.author | Mehra, Rohit | |
dc.date.accessioned | 2023-03-03T21:08:26Z | |
dc.date.available | 2024-03-03 16:08:18 | en |
dc.date.available | 2023-03-03T21:08:26Z | |
dc.date.issued | 2023-02 | |
dc.identifier.citation | Cantley, Richard L.; Wang, Xiaoming; Reichert, Zachery R.; Chinnaiyan, Arul M.; Mannan, Rahul; Cao, Xuhong; Spratt, Daniel E.; Vaishampayan, Ulka N.; Alumkal, Joshi J.; Morgan, Todd M.; Palapattu, Ganesh; Davenport, Matthew S.; Pantanowitz, Liron; Mehra, Rohit (2023). "Metastatic prostate cancer diagnosed by fine-needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates." Cancer Cytopathology 131(2): 117-135. | |
dc.identifier.issn | 1934-662X | |
dc.identifier.issn | 1934-6638 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/175884 | |
dc.description.abstract | IntroductionThe diagnosis of metastatic prostatic cancer (MPC) by fine needle aspiration (FNA) can usually be rendered by typical cytomorphologic and immunohistochemical (IHC) features. However, MPC diagnosis may be complicated by transformation to atypical phenotypes such as small cell carcinoma, typically under pressure from androgen deprivation therapy (ADT). Predictive and prognostic biomarkers can also be assessed by IHC. This study illustrates how careful assessment of cytologic and biomarker features may provide therapeutic and prognostic information in MPC.DesignWe reviewed our anatomic pathology archives for MPC diagnosed by FNA from January 2014 to June 2021. Clinical histories, cytology slides, and cell blocks were reviewed. Extensive IHC biomarker workup was performed, including markers of prostate lineage, cell-cycle dysfunction, Ki-67, neuroendocrine markers, PDL1, and androgen receptor splice variant 7. Cases were reclassified into three categories: conventional type, intermediary type, and high-grade neuroendocrine carcinoma (HGNC).ResultsEighteen patients were identified. Twelve had conventional MPC, including six of six ADT-naive patients. Six of twelve (50%) with prior ADT were reclassified as intermediary or HGNC. Four intermediary cases included two with squamous differentiation and two with pro-proliferative features. Two HGNC cases had typical small cell carcinoma cytomorphology. Expression of PDL1 was�identified in�two cases and ARv7 in three cases. Five of five intermediary and HGNC patients died of disease versus six of eleven with with conventional type.ConclusionsAggressive cytomorphologic variants were commonly identified in patients with prior ADT. Identification of nonconventional cytomorphology and increased proliferation can provide important prognostic information. Recognition of these changes is important for an accurate diagnosis, and the identification of high-grade variants can affect therapeutic decision-making. Clinically actionable biomarkers such as PDL1 and ARv7 can be assessed by IHC.Aggressive cytomorphologic variants of metastatic prostate cancer are common in patients treated with androgen deprivation. Recognition of these changes is important for accurate diagnosis, and identification of high-grade variants can impact therapeutic decision making. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.publisher | Springer | |
dc.subject.other | small cell carcinoma | |
dc.subject.other | transdifferentiation | |
dc.subject.other | androgen receptor (AR) | |
dc.subject.other | cytopathology | |
dc.subject.other | fine needle aspiration | |
dc.subject.other | neuroendocrine | |
dc.subject.other | prostate cancer | |
dc.title | Metastatic prostate cancer diagnosed by fine-needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175884/1/cncy22652_am.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/175884/2/cncy22652.pdf | |
dc.identifier.doi | 10.1002/cncy.22652 | |
dc.identifier.source | Cancer Cytopathology | |
dc.identifier.citedreference | Antonarakis ES, Lu C, Wang H, et�al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371 ( 11 ): 1028 - 1038. doi: 10.1056/nejmoa1315815 | |
dc.identifier.citedreference | Sailer V. Metastatic prostate cancer. In: Robinson B, Mosquera J, Ro J, Divatia M, eds. Precision Molecular Pathology of Prostate Cancer. Molecular Pathology Library. Springer; 2018. | |
dc.identifier.citedreference | Hamdy FC, Donovan JL, Lane JA, et�al. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. Health Technol Assess. 2020; 24 ( 37 ): 1 - 176. doi: 10.3310/hta24370 | |
dc.identifier.citedreference | Donnelly AE, Den R. Radiotherapy for prostate cancer. In: Trabulsi EJ, Lallas CD, Lizardi-Calvaresi AE, eds. Chemotherapy and Immunotherapy in Urologic Oncology. Springer; 2021. | |
dc.identifier.citedreference | Reyes C, Groshel C, Given R. Androgen deprivation therapy. In: Trabulsi EJ, Lallas CD, Lizardi-Calvaresi AE, eds. Chemotherapy and Immunotherapy in Urologic Oncology. Springer; 2021. | |
dc.identifier.citedreference | Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018; 378 ( 7 ): 645 - 657. doi: 10.1056/nejmra1701695 | |
dc.identifier.citedreference | Bubendorf L, Sch�pfer A, Wagner U, et�al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000; 31 ( 5 ): 578 - 583. doi: 10.1053/hp.2000.6698 | |
dc.identifier.citedreference | Albadri ST, Salom�o D. Metastatic prostate adenocarcinoma to cervical lymph nodes: an unusual diagnosis on fine-needle aspiration biopsy. J Am Soc Cytopathol. 2021; 10 ( 2 ): 231 - 238. doi: 10.1016/j.jasc.2020.08.009 | |
dc.identifier.citedreference | Gan Q, Joseph CT, Guo M, Zhang M, Sun X, Gong Y. Utility of NKX3.1 immunostaining in the detection of metastatic prostatic carcinoma on fine-needle aspiration smears. Am J Clin Pathol. 2019; 152 ( 4 ): 495 - 501. doi: 10.1093/ajcp/aqz063 | |
dc.identifier.citedreference | Abdulfatah E, Reichert ZR, Davenport MS, et�al. De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome. Med Oncol. 2021; 38 ( 3 ): 26. doi: 10.1007/s12032-021-01473-2 | |
dc.identifier.citedreference | Abdulfatah E, Fine SW, Lotan T, Mehra R. De novo neuroendocrine features in prostate cancer. Hum Pathol. 2022; 127: 112 - 122. doi: 10.1016/j.humpath.2022.07.002 | |
dc.identifier.citedreference | Beltran H, Hruszkewycz A, Scher HI, et�al. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res. 2019; 25 ( 23 ): 6916 - 6924. doi: 10.1158/1078-0432.CCR-19-1423 | |
dc.identifier.citedreference | Cackowski FC, Kumar-Sinha C, Mehra R, et�al. Double-negative prostate cancer masquerading as a squamous cancer of unknown primary: a clinicopathologic and genomic sequencing-based case study. JCO Precis Oncol. 2020; 4: PO.20.00309. | |
dc.identifier.citedreference | Parwani AV, Ali SZ. Prostatic adenocarcinoma metastases mimicking small cell carcinoma on fine-needle aspiration. Diagn Cytopathol. 2002; 27 ( 2 ): 75 - 79. doi: 10.1002/dc.10146 | |
dc.identifier.citedreference | Schiewer MJ, Augello MA, Knudsen KE. The AR dependent cell cycle:�mechanisms and cancer relevance. Mol Cell Endocrinol. 2012; 352 ( 1-2 ): 34 - 45. doi: 10.1016/j.mce.2011.06.033 | |
dc.identifier.citedreference | de Brot S, Mongan NP. The cell cycle and androgen signaling interactions in prostate cancer. In: Robinson B, Mosquera J, Ro J, Divatia M, eds. Precision Molecular Pathology of Prostate Cancer. Molecular Pathology Library. Springer; 2018. | |
dc.identifier.citedreference | Pisano C, Tucci M, Di Stefano RF, et�al. Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: current and future clinical implications. Crit Rev Oncol Hematol. 2021; 157: 103185. doi: 10.1016/j.critrevonc.2020.103185 | |
dc.identifier.citedreference | Helsen C, Van den Broeck T, Voet A, et�al. Androgen receptor antagonists for prostate cancer therapy. Endocr Relat Cancer. 2014; 21 ( 4 ): T105 - T118. doi: 10.1530/erc-13-0545 | |
dc.identifier.citedreference | Shah RB, Mehra R, Chinnaiyan AM, et�al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004; 64 ( 24 ): 9209 - 9216. doi: 10.1158/0008-5472.can-04-2442 | |
dc.identifier.citedreference | Tamada S, Iguchi T, Kato M, et�al. Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer. Oncotarget. 2018; 9 ( 97 ): 36966 - 36974. doi: 10.18632/oncotarget.26426 | |
dc.identifier.citedreference | Lotan TL. PI3K/Akt/mTOR/PTEN and ERK/MAPK pathways. In: Robinson B, Mosquera J, Ro J, Divatia M, eds. Precision Molecular Pathology of Prostate Cancer. Molecular Pathology Library. Springer; 2018. | |
dc.identifier.citedreference | Gopalan A, Al-Ahmadie H, Chen YB, et�al. Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series. Histopathology. 2022; 81 ( 2 ): 246 - 254. doi: 10.1111/his.14707 | |
dc.identifier.citedreference | Manucha V, Henegan J. Clinicopathologic diagnostic approach to aggressive variant prostate cancer. Arch Pathol Lab Med. 2020; 144 ( 1 ): 18 - 23. doi: 10.5858/arpa.2019-0124-ra | |
dc.identifier.citedreference | Bryden AA, Freemont AJ, Clarke NW, George NJ. Ki-67 index in metastatic prostate cancer. Eur Urol. 2001; 40 ( 6 ): 673 - 676. doi: 10.1159/000049856 | |
dc.identifier.citedreference | Haffner MC, Guner G, Taheri D, et�al. Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer. Am J Pathol. 2018; 188 ( 6 ): 1478 - 1485. doi: 10.1016/j.ajpath.2018.02.014 | |
dc.identifier.citedreference | Sharma M, Yang Z, Miyamoto H. Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer. Medicine (Baltim). 2019; 98 ( 38 ): e17257. doi: 10.1097/md.0000000000017257 | |
dc.identifier.citedreference | K�ronya Z, S�k�sd F, Varga L, et�al. ERG expression can predict the outcome of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. Urol Oncol. 2019; 37 ( 4 ): 289.e1 - 289.e9. doi: 10.1016/j.urolonc.2018.12.007 | |
dc.identifier.citedreference | Tomlins SA, Rhodes DR, Perner S, et�al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005; 310 ( 5748 ): 644 - 648. doi: 10.1126/science.1117679 | |
dc.identifier.citedreference | Jamaspishvili T, Berman DM, Ross AE, et�al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018; 15 ( 4 ): 222 - 234. doi: 10.1038/nrurol.2018.9 | |
dc.identifier.citedreference | Tsai H, Morais CL, Alshalalfa M, et�al. Cyclin D1 loss distinguishes prostatic small-cell carcinoma from most prostatic adenocarcinomas. Clin Cancer Res. 2015; 21 ( 24 ): 5619 - 5629. doi: 10.1158/1078-0432.ccr-15-0744 | |
dc.identifier.citedreference | Hu CD, Choo R, Huang J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front Oncol. 2015; 5 ( 90 ). doi: 10.3389/fonc.2015.00090 | |
dc.identifier.citedreference | Obata H, Shiota M, Akitake N, et�al. Differential risk of castration resistance after initial radical prostatectomy or radiotherapy for prostate cancer. Anticancer Res. 2017; 37 ( 10 ): 5631 - 5637. | |
dc.identifier.citedreference | Udager AM, Shi Y, Tomlins SA, et�al. Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. Prostate. 2014; 74 ( 12 ): 1199 - 1208. doi: 10.1002/pros.22836 | |
dc.identifier.citedreference | Mehra R, Tomlins SA, Yu J, et�al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008; 68 ( 10 ): 3584 - 3590. doi: 10.1158/0008-5472.can-07-6154 | |
dc.identifier.citedreference | Byun SS, Lee M, Hong SK, Lee H. Elevated Ki-67 (MIB-1) expression as an independent predictor for unfavorable pathologic outcomes and biochemical recurrence after radical prostatectomy in patients with localized prostate cancer: a propensity score matched study. PLoS One. 2019; 14 ( 11 ): e0224671. doi: 10.1371/journal.pone.0224671 | |
dc.identifier.citedreference | Kammerer-Jacquet SF, Ahmad A, M�ller H, et�al. Ki-67 is an independent predictor of prostate cancer death in routine needle biopsy samples: proving utility for routine assessments. Mod Pathol. 2019; 32 ( 9 ): 1303 - 1309. doi: 10.1038/s41379-019-0268-y | |
dc.identifier.citedreference | Lotan TL, Tomlins SA, Bismar TA, et�al. Report from the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular biomarkers in prostate cancer. Am J Surg Pathol. 2020; 44 ( 7 ): e15 - e29. doi: 10.1097/PAS.0000000000001450 | |
dc.identifier.citedreference | Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA - Cancer J Clin. 2022; 72 ( 1 ): 7 - 33. doi: 10.3322/caac.21708 | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.